The S239P ERBB4-mutation that we observed in our erlotinib-treated EGFR/NRAS/TP53/ERBB4/DDR2 co-mutated case showing PR had not been previously reported in NSCLC [51]. This evidence concerns the gene TP53 and non-small cell lung carcinoma.